title: First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
mesh_terms: D000367:Age Factors; D016190:Carboplatin / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D014571:Urologic Neoplasms / Q000188:drug therapy*; D019459:Urothelium
chemical_list: D016190:Carboplatin; D002945:Cisplatin